Chronic Kidney Disease and Progressive Renal Failure

Core Idea

CKD is characterized by progressive loss of nephron function (GFR decline) and albuminuria. The hyperfiltration hypothesis posits that remaining nephrons increase single-nephron GFR, accelerating their own damage through glomerular hypertension and proteinuria.

How It's Best Learned

Use eGFR to stage CKD (stages 1–5 by GFR). Study modifiable risk factors: hypertension control, proteinuria reduction, glycemic management. Understand compensatory mechanisms that maintain balance until ~75% of nephrons are lost.

Common Misconceptions

Microalbuminuria is not benign—it is a marker of progressive glomerulosclerosis. Creatinine is a poor marker of GFR in advanced CKD; cystatin C is more accurate.

Explainer

The kidneys maintain homeostasis through roughly one million nephrons, each filtering, reabsorbing, and secreting solutes to generate urine. From your study of renal physiology and GFR, you know that filtration normally runs at 90–120 mL/min and declines with age and disease. In chronic kidney disease (CKD), nephrons are permanently lost — from diabetic glomerulosclerosis, hypertensive nephrosclerosis, chronic glomerulonephritis, or other insults — and unlike most organs, the kidney cannot regenerate functional nephron units. Surviving nephrons adapt, but adaptation itself drives further damage.

This is the core of the hyperfiltration hypothesis. When nephron mass is reduced, remaining nephrons increase their individual filtration rate to partially compensate for total GFR loss. Afferent arterioles dilate, glomerular pressure rises, and each nephron handles a larger plasma volume. Short term, this masks total GFR loss — a patient with 50% nephron loss may have only a modest GFR decline. But elevated intraglomerular pressure causes physical stress on the glomerular capillary wall, promoting mesangial expansion, podocyte damage, and proteinuria. Protein in the tubular filtrate is directly toxic to tubular cells. The result is a self-amplifying cycle: nephron loss → hyperfiltration → proteinuria → tubular injury → more nephron loss.

CKD is staged by eGFR from stage 1 (eGFR ≥90, with markers of kidney damage) through stage 5 (eGFR <15, kidney failure). Clinical management targets the drivers of progression. From your hypertension background, you know that RAAS blockade (ACE inhibitors or ARBs) reduces both systemic blood pressure and intraglomerular pressure specifically, by dilating the efferent arteriole — this reduces the hydraulic stress driving proteinuria. In diabetic nephropathy, tight glycemic control and SGLT2 inhibitors further reduce hyperfiltration. Proteinuria itself is now a therapeutic target: the magnitude of albuminuria independently predicts rate of GFR decline.

Why does creatinine underperform as a GFR marker in advanced CKD? Creatinine is both filtered and secreted by the tubules; as GFR falls, the secreted fraction rises, maintaining serum creatinine lower than true filtration would predict. Cystatin C, filtered but not secreted or reabsorbed, provides a cleaner GFR estimate. This matters clinically: a patient with advanced CKD may have an apparently stable serum creatinine while actively losing nephrons — hyperfiltration and tubular secretion together mask the decline until the reserve is exhausted. The steep deterioration seen in late-stage CKD reflects this unmasking: the compensation fails and GFR drops rapidly.